Panel Recommends Listing 9 Substances in Carcinogen Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

ARLINGTON, Va-A scientific panel has recommended listing nine substances as either “known” or “reasonably anticipated” to be human carcinogens. If upheld after review, the substances will be listed in the 10th “Report on

 ARLINGTON, Va—A scientific panel has recommended listing nine substances as either “known” or “reasonably anticipated” to be human carcinogens. If upheld after review, the substances will be listed in the 10th “Report on Carcinogens,” prepared by the National Toxicology Program (NTP) and scheduled for publication in 2002.

The panel voted to upgrade beryllium and beryllium compounds (substances used in fiber optics, aerospace, and other industrial applications) from “reasonably anticipated” to “known” human carcinogens. They recommended listing vinyl bromide and vinyl fluoride as “known” human carcinogens. Vinyl bromide’s primary use is in making flame-retardant synthetic fibers. Vinyl fluoride is a chemical used in making polyvinylfluoride, which is used in the plastics industry.

The panel also recommended listing two other chemicals used in make products flame resistant as “reasonable anticipated” to be human carcinogens: 2,2-bis-(bromomethyl)l-1,3-propanediol used in unsaturated polyester resins, molded products, and rigid polyurethane foam, and 2,3-dibromo-1-propanol, also found in pesticides and drug preparations.

Three other substances were cited as “reasonably anticipated” to be human carcinogens: dimethylbenzidine dyes used in some textiles and plastics; IQ, found in cooked meat and fish; and styrene-7,8-oxide, use in preparing fragrances.

Recent Videos
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content